3-(1H-imidazol-1-yl)-N-methylpropan-1-amine | 112086-54-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(1H-imidazol-1-yl)-N-methylpropan-1-amine
• 英文别名: [3-(1H-imidazol-1-yl)propyl]methylamine；1-(3-methylamino-prop-1-yl)-imidazole；1-(3-N-methylaminopropyl)imidazole；[3-(1H-imidazol-1-yl)propyl](methyl)amine；3-imidazol-1-yl-N-methylpropan-1-amine
• CAS: 112086-54-1
• 化学式: C₇H₁₃N₃
• mdl: MFCD09031545
• 分子量: 139.2
• InChiKey: ZPMDRIAJBDFGCZ-UHFFFAOYSA-N

物化性质

• 沸点：
  285.9±23.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  nocathiacin I 、 3-(1H-imidazol-1-yl)-N-methylpropan-1-amine 以 水 为溶剂， 生成 N-[1-amino-3-[3-imidazol-1-ylpropyl(methyl)amino]-1-oxopropan-2-yl]-2-[(1S,18S,21E,28S,29S,30S)-30-[(2S,4S,5R,6S)-5-(dimethylamino)-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-9,52-dihydroxy-18-[(1R)-1-hydroxyethyl]-21-(1-methoxyethylidene)-16,19,26,31,42,46-hexaoxo-32,43,54-trioxa-3,13,23,49-tetrathia-7,17,20,27,45,51,52,55,56,57-decazadecacyclo[26.16.6.229,40.12,5.112,15.122,25.138,41.147,50.06,11.034,39]heptapentaconta-2(57),4,6,8,10,12(56),14,22(55),24,34(39),35,37,40,47,50-pentadecaen-8-yl]-1,3-thiazole-4-carboxamide
  参考文献：
  名称：

  Nocathiacin I类似物：新型半合成噻唑基肽抗生素的合成，体外和体内生物学活性。

  摘要：

  合成了几种Nocathiacin I类似物（4-35）并评估了其抗菌活性。这些半合成类似物中的大多数在体外和体内的抗菌活性均保持为1。

  DOI：

  10.1016/j.bmcl.2004.08.058
• 作为产物：
  描述：

  在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 3-(1H-imidazol-1-yl)-N-methylpropan-1-amine
  参考文献：
  名称：

  The First Potent Inhibitors for Human Glutaminyl Cyclase:  Synthesis and Structure−Activity Relationship

  摘要：

  The first effective inhibitors for human glutaminyl cyclase (QC) are described. The structures are developed by applying a ligand-based optimization approach starting from imidazole. Screening of derivatives of that heterocycle led to compounds of the imidazol-1-yl-alkyl thiourea type as a lead scaffold. A library of thiourea derivatives was synthesized, resulting in an inhibitory improvement by 2 orders of magnitude, leading to 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea as a potent inhibitor. Systematic exploitation of the scaffold revealed a strong impact on the inhibitory efficacy and resulted in the development of imidazole-propyl-thioamides as another new class of potent inhibitors. A flexible alignment of the most potent compounds of the thioamide and thiourea class and a QC substrate revealed a good match of characteristic features of the molecules, which suggests a similar binding mode of both inhibitors and the substrate to the active site of QC.

  DOI：

  10.1021/jm050756e

文献信息

• [EN] 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 2-CYANOISOINDOLINE POUR LE TRAITEMENT DU CANCER
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2017158388A1

  公开（公告）日：2017-09-21

  The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.

  这项发明涉及公式I的新化合物，这些化合物是去泛素化酶（DUBs）和/或去泛素化酶的抑制剂。具体来说，该发明涉及抑制泛素C端水解酶7或泛素特异性肽酶7（USP7）。该发明还涉及这些化合物的制备方法以及它们在癌症治疗中的应用。
• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang Kenneth He

  公开号：US20080119457A1

  公开（公告）日：2008-05-22

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q 1 , Q 2 , Q 3 , R 31 , and R 41 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  公开了公式I的化合物和药用盐，其中A、Q1、Q2、Q3、R31和R41如本文所定义。公式I的化合物在治疗与细胞增殖相关的疾病和/或病况方面具有用途，如癌症、炎症、关节炎、血管生成等。还公开了包括本发明化合物的药物组合物以及使用这些化合物治疗上述病况的方法。
• MELAMPOMAGNOLIDE B DERIVATIVES
  申请人：Janganati Venumadhav

  公开号：US20150133444A1

  公开（公告）日：2015-05-14

  The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for treating cancer in humans.

  本公开提供了槲皮素B（MMB）的衍生物，包括碳酸酯、氨基甲酸酯和硫代氨基甲酸酯。这些衍生物可以通过MMB三唑中间体合成。这些衍生物对于治疗人类癌症是有用的。
• 8-Substituted isoquinoline derivative and the use thereof
  申请人：Kaneko Shunsuke

  公开号：US20100261701A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及一种由以下式（1）表示的化合物： 其中D1，A1，D2，R1，D3和R2分别具有与本说明书中定义的相同含义或其盐。由式（1）表示的化合物或其盐具有IKKβ抑制活性等，对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
• Pyrrole substituted 2-indolinone protein kinase inhibitors
  申请人：——

  公开号：US20020156292A1

  公开（公告）日：2002-10-24

  The present invention relates to pyrrole substituted 2 -indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯替代的2-吲哚酮化合物及其药学上可接受的盐，这些化合物调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用处。